证券代码：603567 证券简称：珍宝岛 公告编号：临 2022-040 黑龙江珍宝岛药业股份有限公司 关于参加"2022 年投资者网上集体接待日活动 暨业绩说明会"的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强与投资者的互动交流，黑龙江珍宝岛药业股份有限公司（以 下简称"公司"）将参加由黑龙江省上市公司协会联合深圳市全景网络有限公司 共同举办的"黑龙江省上市公司 2022 年度投资者网上集体接待日活动暨业绩说 明会"，现将有关事项公告如下： 为促进上市公司规范运作、健康发展，增强上市公司信息透明度，加强与广 大投资者沟通交流，进一步提升投资者关系管理水平，黑龙江省上市公司协会联 合深圳市全景网络有限公司，在"全景路演"举办"黑龙江省上市公司 2022 年 投资者网上集体接待日活动暨业绩说明会"。投资者可以登陆"全景路演"网站 （https://rs.p5w.net/html/132395.shtml）参与公司本次投资者集体接待日活 动,时间为 2022 年 5 月 12 日（周四）14:30 至 ...

Financial Performance - The company's operating revenue for 2021 was RMB 4,126,813,896.18, representing a 21.24% increase compared to RMB 3,403,747,280.97 in 2020[21]. - The net profit attributable to shareholders of the listed company was RMB 332,099,672.96, a decrease of 23.88% from RMB 436,285,785.59 in the previous year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 79,236,536.87, down 77.92% from RMB 358,933,556.59 in 2020[21]. - The net cash flow from operating activities was negative at RMB -433,936,940.94, a decline of 379.64% compared to RMB 155,178,025.16 in 2020[21]. - The total assets at the end of 2021 were RMB 11,506,076,750.01, an increase of 12.43% from RMB 10,234,312,842.17 at the end of 2020[21]. - The net assets attributable to shareholders of the listed company increased by 28.18% to RMB 7,042,918,942.75 from RMB 5,494,448,424.79 at the end of 2020[21]. - Basic earnings per share decreased by 25.24% to 0.3841 RMB compared to 2020[24]. - The weighted average return on equity dropped to 5.664% from 8.15% in 2020, a decrease of 2.49 percentage points[24]. - The gross profit margin for the overall business decreased by 22.99 percentage points to 33.75% due to rising costs[106]. - The company achieved a revenue of 4.127 billion RMB, representing a year-on-year growth of 21.24%[98]. Cash Flow and Investments - The company reported a significant increase in cash flow from financing activities, which rose by 173.00% to approximately ¥797.46 million from ¥292.11 million, mainly due to increased funds raised from a private placement[104]. - The company’s cash and cash equivalents at the end of the reporting period totaled approximately ¥107.05 million, primarily restricted due to bank guarantees[133]. - The company reported a significant increase in long-term equity investments, reaching approximately ¥644.88 million, a 43.42% increase compared to the previous period[130]. - The company's debt investments rose to approximately ¥198.08 million, reflecting a 41.41% increase due to increased promotional expenses[130]. - The company experienced a substantial increase in development expenditures, amounting to approximately ¥139.34 million, which is an increase of 182.86% compared to the previous period, attributed to increased capitalized R&D expenses[130]. Research and Development - The company established a comprehensive R&D system with over 200 personnel and seven major R&D platforms, focusing on both traditional Chinese medicine and chemical drugs[53]. - The company has 41 ongoing projects in raw materials and generic drug formulations, aiming to enhance product competitiveness in major therapeutic areas[53]. - The company is focusing on innovative drug research and development, expanding its specialized R&D team, and enhancing overall R&D capabilities[150]. - The company has several ongoing R&D projects, including innovative drugs targeting severe influenza and liver cancer, currently in Phase I clinical trials[151]. - The company’s R&D investment in the "Anti-Influenza Virus New Drug" project was 1,666.57 million RMB, with a significant decrease of 51.65% compared to the previous year[159]. - The company’s R&D investment in the "Pan FGFR Kinase Inhibitor" project was 273.56 million RMB, reflecting a decrease of 53.27% compared to the previous year[159]. - The company is focusing on developing traditional Chinese medicine (TCM) and high-end formulations in chemical and biological drugs, with a strategic shift from product advantages to therapeutic domain advantages[180]. - The company aims to enhance its product pipeline by focusing on cardiovascular, respiratory, orthopedic, oncology, digestive, diabetes, and mental health fields, while also promoting the development of innovative TCM products[181]. Market Strategy and Operations - The company has established a comprehensive marketing network covering the entire country, implementing a "self-operated + all-channel + all-terminal" market development strategy[40]. - The company is focusing on expanding its biopharmaceutical sector, with a new investment cooperation agreement signed for a biopharmaceutical R&D base in Hangzhou[42]. - The company is actively expanding its market presence by optimizing marketing strategies and deepening its service network[76]. - The company is committed to continuous investment in traditional Chinese medicine R&D, collaborating with renowned universities and research institutions to enhance product development[80]. - The company is exploring innovative commercial models, including internet hospitals and logistics solutions, to enhance its service offerings[69]. - The company is focusing on the development of smart factories and intelligent manufacturing to improve production efficiency and product quality[86]. - The company is actively seeking acquisition opportunities to enrich its product pipeline and support steady growth, particularly in overseas markets[181]. - The company emphasizes a three-pronged marketing strategy focusing on academic promotion, market access, and channel development to expand its reach in both high-tier hospitals and grassroots medical markets[184]. Challenges and Risks - The company faced significant procurement cost increases due to rising prices of metals, traditional Chinese medicine materials, and logistics costs influenced by external factors such as the pandemic and environmental policies[192]. - The company is responding to policy changes in the pharmaceutical industry, including the normalization of centralized procurement and the adjustment of medical insurance directories, which significantly impact the market landscape[187]. - The company experienced a 66.43% decline in sales volume for its main product, the injection of blood stasis-removing agent, due to pandemic-related impacts[113]. - The revenue from traditional Chinese medicine preparations decreased by 32.05%, while the gross profit margin fell by 3.23 percentage points, influenced by industry policies and the pandemic[112]. Subsidiaries and Acquisitions - The company established a wholly-owned subsidiary, Zhejiang Suoao Biotechnology Co., Ltd., with a registered capital of RMB 200 million, focusing on technology services and medical research[165]. - The company invested RMB 400 million in Zhejiang Teruisi Pharmaceutical Co., Ltd., acquiring a 16.6665% stake, which increased to 17.0211% due to a shareholder exit[166]. - The company’s subsidiary, Harbin Zhenbao Pharmaceutical Co., Ltd., reported total assets of RMB 1,795.38 million, a decrease of 7.96% from the beginning of the period, with a net profit of RMB 80.09 million, down 69.00% year-on-year[175]. - The company’s subsidiary, Bozhou Chinese Medicine Trading Center Co., Ltd., reported total assets of RMB 2,334.32 million, a decrease of 0.35%, with a net profit of RMB 235.14 million, an increase of 377.45% year-on-year[176].

Financial Performance - The company's revenue for Q1 2022 was CNY 1,003,658,954.36, representing a year-on-year increase of 38.07%[6] - Net profit attributable to shareholders was CNY 157,983,557.32, with a slight increase of 1.72% compared to the same period last year[6] - Total operating revenue for Q1 2022 reached ¥1,004,694,007.42, a significant increase from ¥726,899,141.49 in Q1 2021, representing an increase of approximately 38.2%[29] - Net profit attributable to shareholders of the parent company for Q1 2022 was ¥157,983,557.32, compared to ¥155,310,850.70 in Q1 2021, showing a growth of about 1.1%[32] - The total comprehensive income attributable to the parent company for Q1 2022 was ¥157,983,557.32, an increase from ¥155,310,850.70 in Q1 2021, representing a growth of approximately 1.08%[34] Cash Flow - The net cash flow from operating activities reached CNY 77,223,705.06, showing a significant increase of 121.99% year-on-year[6] - The net cash flow from operating activities for Q1 2022 was ¥77,223,705.06, a significant improvement compared to a negative cash flow of ¥351,162,846.90 in Q1 2021[37] - The total cash inflow from operating activities in Q1 2022 was ¥975,678,578.45, up from ¥660,996,987.02 in the same period last year, indicating a growth of approximately 47.5%[37] - The cash outflow from operating activities in Q1 2022 was ¥898,454,873.39, down from ¥1,012,159,833.92 in Q1 2021, reflecting a decrease of about 11.3%[37] - The net cash flow from financing activities for Q1 2022 was ¥53,986,255.30, a recovery from a negative cash flow of -¥38,018,294.92 in Q1 2021[37] Assets and Liabilities - Total assets at the end of the reporting period were CNY 11,786,477,883.18, an increase of 2.44% from the end of the previous year[9] - Total liabilities increased to ¥4,577,308,066.32 in Q1 2022 from ¥4,454,890,583.10 in Q1 2021, reflecting a rise of approximately 2.8%[29] - The total equity attributable to shareholders of the parent company rose to ¥7,200,999,491.68 in Q1 2022, up from ¥7,042,918,942.75 in Q1 2021, indicating an increase of about 2.2%[29] - The company has a total non-current asset value of ¥4,915,111,671.25, compared to ¥4,830,002,082.62 previously[24] Shareholder Information - Total number of common stock shareholders at the end of the reporting period is 17,850[16] - The largest shareholder, Heilongjiang Chuangda Group Co., Ltd., holds 571,485,300 shares, representing 60.67% of total shares[16] Operating Costs and Expenses - Operating costs for Q1 2022 were ¥851,272,779.55, compared to ¥605,565,649.67 in Q1 2021, marking an increase of approximately 40.5%[29] - Research and development expenses for Q1 2022 were ¥11,020,378.79, slightly down from ¥11,024,356.07 in Q1 2021, indicating a stable R&D investment[30] - The company reported a decrease in sales expenses to ¥110,838,260.50 in Q1 2022 from ¥142,472,135.29 in Q1 2021, a reduction of about 22.3%[30] - The company’s financial expenses decreased to ¥31,977,842.54 in Q1 2022 from ¥34,370,344.56 in Q1 2021, a decline of about 11.6%[30] Investment Income - Investment income surged by 190.02%, attributed to the distribution of profits from associated companies[13] - The total cash inflow from investment activities in Q1 2022 was ¥25,000,849.15, compared to ¥12,815,024.83 in Q1 2021, representing a growth of approximately 95%[37] Other Financial Metrics - Basic earnings per share decreased by 8.3% to CNY 0.1677[6] - The basic and diluted earnings per share for Q1 2022 were both ¥0.17, a slight decrease from ¥0.18 in Q1 2021[34] - The weighted average return on equity was 2.22%, down by 0.56 percentage points compared to the previous year[9] - The company has no significant new product or technology developments reported in the current quarter[19]

证券代码：603567 证券简称：珍宝岛 编号：2022-001 √特定对象调研□分析师会议□媒体采访□业绩说明会 投资者关系活 □新闻发布会□路演活动□现场参观 动类别 □其他（请文字说明其他活动内容） 参与单位名称 上海冰河资本刘春茂、东方阿尔法基金乔海英、长江证券朱学辉、 泰康资产杨磊 及人员姓名 公司领导对公司基本情况做了系统介绍，参会机构与公司相 关领导进行了沟通交流，主要内容如下： 1、中药创新药未来的布局？对公司影响如何？ 答：公司正在布局中药创新药产品，根据不同品种特点做到 投资者关系活动 创新药上市还需要时间。现在有的品种马上进行二期临床，还有 主要内容介绍 的品种在做药学研究，预计明年年底有望拿到批件，还有其他一 些已经立项。其他中药品种的补充也在不断引进有临床和市场价 值的产品，不断补充短线产品和几个大的品种，今年有销售预期。 中药创新药的研发及引进，将会进一步提升公司主营业务产品核 黑龙江珍宝岛药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|--------------------------------------- ...

Financial Performance - The company's operating revenue for Q3 2021 was ¥1,072,990,343.47, representing a year-on-year increase of 160.39%[7] - The net profit attributable to shareholders was a loss of ¥33,852,631.99, a decrease of 160.06% compared to the same period last year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥44,698,960.45, with a significant increase of 349.03% year-to-date[7] - The basic and diluted earnings per share were both -¥0.0398, reflecting a decrease of 159.94% year-on-year[9] - Revenue for the period from the beginning of the year to the end of the reporting period was 52.27 million, mainly driven by the growth in traditional Chinese medicine business[14] - Operating costs for the same period reached 137.34 million, also attributed to the increase in traditional Chinese medicine business[14] - The company reported a net profit of CNY 3.24 billion for the first nine months of 2021, up from CNY 2.99 billion in the same period last year[30] - Total operating revenue for the first three quarters of 2021 reached RMB 2,704,740,106.96, a 52.5% increase from RMB 1,780,776,566.44 in the same period of 2020[34] - Operating profit for the third quarter of 2021 was RMB 296,631,230.15, compared to RMB 315,434,418.04 in the third quarter of 2020, reflecting a decrease of 5.5%[36] - Net profit attributable to shareholders of the parent company for the third quarter of 2021 was RMB 242,419,593.26, slightly up from RMB 240,821,172.25 in the same quarter of 2020, indicating a growth of 0.7%[36] Assets and Liabilities - The total assets at the end of the reporting period were ¥10,234,117,571.86, showing a slight decrease of 0.00% compared to the end of the previous year[9] - The equity attributable to shareholders increased to ¥5,737,028,476.17, marking a year-on-year growth of 4.42%[9] - The company reported a significant decrease of 79.83% in cash and cash equivalents at the end of the reporting period, primarily due to payments for herbal medicine and R&D expenses[12] - Inventory increased by 32.49% at the end of the reporting period, mainly due to an increase in herbal materials[12] - Long-term equity investments at the end of the reporting period amounted to 40.89 million, primarily due to increased investment payments to associated companies[14] - The company's total assets amounted to CNY 10.23 billion, with current assets totaling CNY 5.31 billion[24] - Total liabilities were reported at CNY 4.49 billion, a decrease from CNY 4.73 billion year-over-year[30] - The company’s long-term borrowings stood at CNY 2.12 billion, slightly down from CNY 2.13 billion year-over-year[30] - The company’s total non-current assets amounted to CNY 4.92 billion, an increase from CNY 4.23 billion in the previous year[30] - The company’s total liabilities and equity amounted to CNY 10.23 billion, consistent with the total assets reported[33] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥500,324,395.95, indicating a negative cash flow situation[9] - Net cash flow from operating activities for the period was -337.11 million, mainly due to reduced sales collections during the pandemic and increased payments for raw material purchases[14] - Cash flow from investing activities for the period was 46.11 million, primarily due to increased proceeds from the sale of wholly-owned subsidiary equity[14] - Cash flow from financing activities for the period was -157.28 million, mainly due to adjustments in the borrowing structure[14] - Cash received from borrowings was $520,000,000.00, down from $1,940,000,000.00[42] - Cash paid for debt repayment was $569,000,000.00, compared to $1,372,886,295.00 previously[42] - Cash paid for dividends and interest was $108,895,354.71, a decrease from $425,780,138.16[42] - The net increase in cash and cash equivalents was -$1,240,263,192.14, worsening from -$1,022,404,269.05[42] - The ending balance of cash and cash equivalents was $261,597,089.10, significantly lower than $1,483,056,215.26 at the beginning of the period[42] Shareholder Information - The total number of common shareholders at the end of the reporting period was 16,476[14] - The top ten shareholders held a total of 579.89 million shares, representing 68.29% of the total shares[17] Non-Recurring Gains and Expenses - Non-recurring gains included government subsidies amounting to ¥14,088,525.93 for the year-to-date[10] - The company reported a decrease in tax and additional charges to RMB 49,913,584.26 in 2021 from RMB 102,867,926.50 in 2020, a reduction of 51.5%[34] - Research and development expenses for the first three quarters of 2021 were RMB 37,187,830.90, down 22.7% from RMB 48,094,535.80 in the same period of 2020[34] - The company recorded an investment income of RMB 151,656,264.63 for the first three quarters of 2021, down from RMB 240,122,890.14 in the same period of 2020, a decline of 37.0%[34] - The company reported a significant increase in fixed asset disposal income, amounting to 131.96 million, indicating improved asset management[14] Equity Transactions - The company transferred 100% equity of its wholly-owned subsidiaries to Heilongjiang Zhenbao Island Group for a transfer payment of CNY 423 million, representing 53.36% of the total transfer amount[22] Leasing Standards - The company has not applied the new leasing standards since 2021[43]

Financial Performance - The company's operating revenue for the first half of 2021 was ¥1,630,014,986.26, representing a 19.58% increase compared to ¥1,363,061,918.71 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was ¥276,272,225.25, a 49.77% increase from ¥184,458,216.10 in the previous year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥170,459,049.71, showing a slight increase of 1.47% compared to ¥167,982,588.25 last year[21]. - The basic earnings per share for the first half of 2021 was ¥0.3253, up 49.77% from ¥0.2172 in the same period last year[22]. - The weighted average return on net assets increased to 4.90%, up by 1.38 percentage points from 3.52% in the previous year[22]. - The net cash flow from operating activities decreased by 623.07% to -¥400,995,833.55, compared to ¥76,661,730.92 in the same period last year, primarily due to reduced sales collections during the pandemic[25]. - The total assets at the end of the reporting period were ¥10,059,530,635.84, a decrease of 1.71% from ¥10,234,312,842.17 at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company increased by 5.04% to ¥5,771,192,417.79 from ¥5,494,448,424.79 at the end of the previous year[21]. Business Strategy and Operations - The company plans to expand its traditional Chinese medicine trade business, which contributed to the increase in revenue and profit[22]. - The company operates across multiple sectors including pharmaceutical manufacturing, traditional Chinese medicine, and pharmaceutical commerce, focusing on drug research, production, and sales[30]. - The company has established three major production bases with 22 workshops and 31 production lines, all certified under GMP standards, capable of producing 11 dosage forms[31]. - The company has 45 product varieties with 63 drug production approval numbers, including 24 varieties listed in the National Medical Insurance Directory[31]. - The company emphasizes R&D capabilities, with a core R&D center in Beijing and collaborations with renowned universities and research institutions[32]. - The company has developed a dual-channel trading platform for traditional Chinese medicine, integrating online and offline sales to enhance efficiency and reduce costs[33]. - The procurement strategy includes centralized purchasing for raw materials and strategic procurement to ensure cost-effectiveness and quality control[36]. - The company focuses on dynamic inventory management and budget control in its procurement processes to align with market conditions[38]. - The company implemented a "sales-driven production" model, ensuring production plans are based on sales forecasts and inventory levels[42]. - The medical distribution business accounts for over 98% of sales, serving more than 1,000 clients including hospitals and retail chains[44]. Research and Development - The company has established a research team of nearly 200 people, with over 100 holding advanced degrees or high titles, and invests approximately 3% of its sales revenue annually in R&D[64]. - The company has 4 innovative chemical drugs and 45 generic drugs in development, along with 49 traditional Chinese medicine projects and over 550 formula granules[66]. - The company has successfully registered over 550 common varieties of traditional Chinese medicine formula granules, ensuring strong market competitiveness[69]. - The company holds a total of 155 valid patents, including 92 domestic invention patents and 5 foreign invention patents, enhancing its product value and market competitiveness[70]. - The company has established a complete hospital preparation "industry-university-research" work system, collaborating with numerous well-known hospitals to modernize and industrialize classic formulas[66]. - The company has 11 innovative drugs and biosimilars in its product pipeline, with 3 products approved for clinical trials[65]. - The company has implemented advanced quality control standards, exceeding national drug standards, and has received various quality management certifications[72]. - The company has partnered with top universities and research institutions for traditional Chinese medicine research, enhancing its R&D capabilities[65]. - The company utilizes over 10 advanced technologies in its production processes, significantly improving product quality and safety[71]. Market and Competitive Position - The global pharmaceutical market is projected to reach $1,559.3 billion in 2023, with innovative drugs expected to grow to $1,034.5 billion[50]. - The company focuses on cardiovascular, respiratory, and oncology fields, enhancing clinical value through product line expansion[57]. - The company has been recognized as a well-known Chinese brand and ranked 26th in the "Top 100 Chinese Traditional Medicine Enterprises"[52][55]. - The company has adopted precise marketing strategies in response to healthcare reforms, enhancing purchasing power in medical and retail sectors[56]. - The company emphasizes academic promotion to enhance brand recognition and customer confidence, facilitating market advantage[60]. - The company is committed to sustainable growth through continuous innovation and product structure optimization[61]. Environmental and Social Responsibility - The company has established a dedicated environmental management team to oversee compliance with environmental regulations and standards[130]. - The company conducts annual third-party testing of wastewater and emissions to ensure compliance with relevant environmental standards[132]. - The company has implemented measures to manage and treat waste gases and wastewater, ensuring they meet national standards[132]. - The company has developed a series of environmental protection management regulations to enhance internal oversight and compliance[131]. - The company has achieved compliance with the noise emission standards set by GB12348-2008, with annual third-party testing confirming adherence to Class 2 limits[141]. - Wastewater from production and domestic sources is treated at the company's wastewater treatment station, meeting the GB8978-1996 Class II discharge standards, with quarterly third-party testing conducted[138]. - Solid waste is managed in accordance with national standards, with hazardous waste being collected and stored properly to prevent pollution, and annual contracts signed with qualified disposal companies[142]. - The company has implemented measures to reduce emissions from its boiler room, ensuring compliance with GB13271-2014 standards through effective purification systems[141]. - The company’s wastewater discharge meets the GB8978-1996 Class III standards, with annual third-party testing to ensure compliance[148]. - The company has developed a series of environmental protection regulations, including solid and hazardous waste management protocols, which are reported to the local environmental authority annually[147]. - The company has achieved a zero discharge policy for hazardous waste, maintaining strict records of generation and storage to ensure compliance with legal requirements[149]. - The company’s air emissions from wastewater treatment meet the GB14554-93 Class II standards, with annual third-party testing confirming compliance[148]. - The company donated RMB 4 million to the Heilongjiang Youth Development Foundation to support youth development and improve their growth environment[152]. - The company actively participates in social welfare activities and aims to expand its poverty alleviation efforts to more regions and communities[153]. - The company has implemented various measures to support local education, culture, science, and health initiatives[152]. - The company has been recognized for its contributions to social services and poverty alleviation efforts[152]. - The company has organized activities to support employees in financial difficulty, demonstrating its commitment to corporate social responsibility[152]. Shareholder and Corporate Governance - The largest shareholder, Heilongjiang Chuangda Group Co., Ltd., holds 68.29% of the shares, with 362,000,000 shares pledged[169]. - The second-largest shareholder, Hulin Longpeng Investment Center (Limited Partnership), holds 16.96% of the shares, with 78,200,000 shares pledged[169]. - The total number of common shareholders at the end of the reporting period is 17,636[168]. - The company has not experienced any changes in its total share capital or share structure during the reporting period[168]. - There are no strategic investors or general corporations that have become top ten shareholders due to new share placements[175]. - The company has not disclosed any other significant matters related to shareholder changes or stock incentives during the reporting period[175]. - There are no changes in the controlling shareholder or actual controller during the reporting period[177]. - The total amount of guarantees provided by the company, including those to subsidiaries, is 68,000,000 RMB, which accounts for 11.76% of the company's net assets[164]. - The total amount of guarantees provided to subsidiaries during the reporting period is 27,000,000 RMB, with a balance of 68,000,000 RMB at the end of the reporting period[164]. - The company has provided a joint liability guarantee of 27,000,000 RMB for Heilongjiang Zhenba Pharmaceutical Co., Ltd. and a total loan balance of 55,000,000 RMB as of June 30[164]. - The integrity status of the company and its major stakeholders is good, with no significant debts or court judgments outstanding[157]. - The company has not proposed any profit distribution or capital reserve transfer plans for the reporting period, maintaining a focus on reinvestment[126]. - The company has implemented a short-term incentive system for employees, particularly in R&D and production roles, to enhance motivation and align interests[126].

2021 年第一季度报告 公司代码：603567 公司简称：珍宝岛 黑龙江珍宝岛药业股份有限公司 2021 年第一季度报告 1 / 18 2021 年第一季度报告 一、 二、 11Í 四、 目录 | --- | |----------------| | | | 重要提示 . | | 公司基本情况 . | | 重要事项 . | | 附录 . | 2 / 18 2021 年第一季度报告 单位：元币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人方同华、主管会计工作负责人王磊及会计机构负责人（会计主管人员）王磊保证 季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | |-----------------------------------------------|----------------- ...

Financial Performance - The company's operating revenue for 2020 was approximately RMB 3.40 billion, representing a 3.40% increase compared to RMB 3.29 billion in 2019[22]. - The net profit attributable to shareholders for 2020 was approximately RMB 436.29 million, reflecting a 6.76% increase from RMB 408.65 million in 2019[22]. - The net cash flow from operating activities decreased by 29.76% to approximately RMB 155.18 million in 2020, down from RMB 220.92 million in 2019[22]. - The total assets at the end of 2020 were approximately RMB 10.23 billion, a 13.48% increase from RMB 9.02 billion at the end of 2019[22]. - The basic earnings per share for 2020 was RMB 0.5138, up 6.77% from RMB 0.4812 in 2019[23]. - The weighted average return on equity for 2020 was 8.15%, an increase of 0.15 percentage points from 8.00% in 2019[23]. - The company reported a total net profit of RMB 77.35 million from non-recurring gains and losses in 2020, compared to RMB 67.30 million in 2019[27]. - The company's operating revenue for the current period is approximately ¥3.40 billion, an increase of 3.40% compared to the same period last year[100]. - The total cost for the current period is CNY 1,466,171,294.14, representing a 27.97% increase compared to CNY 1,145,737,272.11 in the previous year[115]. - The gross profit margin for the industrial sector improved by 1.23 percentage points to 85.32% despite a 7.59% increase in revenue[105]. Research and Development - The company has established a comprehensive R&D system, focusing on traditional Chinese medicine, chemical drugs, and biological drugs to drive innovation[32]. - The R&D strategy includes three research institutes located in Beijing, Harbin, and Shanghai, each specializing in different areas of drug development[35]. - The company has 42 ongoing projects in the field of chemical drug research and development, focusing on high-end formulations and generic drugs[36]. - The company has introduced the innovative antiviral drug ZBD1042 (HNC042), completing Phase I clinical bridging trials by the end of December 2020[36]. - The R&D team consists of nearly 200 members, with over 100 holding advanced degrees or high professional titles, and the company invests approximately 3% of its sales revenue annually in R&D[72]. - The company has several innovative drugs in the clinical trial phase, including ZBD1042 for influenza and HZB1006 for liver and stomach cancers[141]. - Research and development (R&D) expenses accounted for 3.65% of the company's total revenue during the reporting period[145]. - The company has expanded its R&D team and initiated self-research on generic drugs, enhancing its R&D capabilities[90]. Market Strategy and Expansion - The company aims to expand its market presence by leveraging its strengths in traditional Chinese medicine while rapidly advancing into chemical and biological drug sectors[32]. - The company is actively expanding its market presence through a B2B2C e-commerce platform for traditional Chinese medicine, with offline points established in major trading markets[48]. - The company has established a comprehensive marketing management service system covering all 32 provinces in China, enhancing its sales network and resource allocation[52]. - The company has developed a detailed marketing strategy that includes five sales regions and a dedicated business department to enhance market coverage[76]. - The company plans to continue expanding its market presence and product distribution strategies in response to changing customer demands and market conditions[111]. - The company aims to enhance its marketing strategy by establishing a service-first approach and optimizing its sales structure[150]. - The company plans to accelerate the development and promotion of oral formulations to increase market presence[150]. Corporate Governance and Compliance - The company’s financial report has been audited and received a standard unqualified opinion from the accounting firm[5]. - The company has confirmed that there are no non-operational fund occupations by controlling shareholders or related parties[8]. - The company has not violated any decision-making procedures regarding external guarantees[8]. - The company has established a quality standard evaluation system and monitoring technology, ensuring that products meet or exceed national standards[62]. - The company has achieved ISO certifications for quality management, environmental management, and health safety management systems, ensuring high standards across operations[63]. - The company has implemented a strategy to assess downstream enterprises' creditworthiness and set different credit limits to mitigate risks related to receivables and bad debts[193]. Social Responsibility and Recognition - The company actively participates in social responsibility initiatives, including donating antiviral medications during the COVID-19 pandemic, enhancing its brand recognition and reputation[83]. - The company has been recognized with multiple awards, including the "2020 Most Growth-Oriented Listed Company in Biomedicine" and "Innovation Award" in the health industry[80]. Financial Management and Investments - The company has initiated a non-public offering project aiming to raise CNY 1.8 billion for various development projects, including innovative drug and generic drug R&D platforms[97]. - The company’s cash and cash equivalents decreased by 39.74% to CNY 1,539,001,617.29, mainly due to payments for R&D and investments[124]. - The company’s investment activities generated a net cash outflow of CNY 1,450,885,630.26, a significant increase of 456.41% compared to the previous year[121]. - The company has not adjusted its cash dividend policy during the reporting period, maintaining a consistent approach to shareholder returns[197]. Industry Trends and Outlook - The pharmaceutical industry in China is projected to reach a terminal sales scale of 1.84 trillion yuan in 2020, with a 2% decline in overall sales due to the pandemic[131]. - The Chinese pharmaceutical industry is undergoing deep transformation, with the elderly population projected to reach 483 million by 2050, driving market growth[168]. - Government healthcare spending is expected to rise from 6.58% to nearly 10% of GDP, providing further support for the pharmaceutical industry[168].

证券代码：603567 证券简称：珍宝岛 公告编号：临 2020-063 黑龙江珍宝岛药业股份有限公司 关于参加投资者网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强与投资者的互动交流，黑龙江珍宝岛药业股份有限公司（以 下简称"公司"）将参加由黑龙江省上市公司协会、深圳市全景网络有限公司共 同举办的"黑龙江省上市公司 2020 年度投资者网上集体接待日"活动，现将有 关事项公告如下： 本次集体接待日活动将通过深圳市全景网络有限公司提供的互联网平台举 行，投资者可以登陆"全景·路演天下"网站（http：//rs.p5w.net）参与公司 本次投资者集体接待日活动,时间为 2020 年 11 月 12 日（周四）14:00 至 16:30。 届时公司财务负责人王磊先生，董事会秘书侯旭志先生将通过网络在线问答 互动的形式，与投资者就公司治理、发展经营情况、融资情况和可持续发展等投 资者关注的问题进行交流。期间，公司高管将全程在线，实时回答投资者的提问。 欢迎广大投资者积极参与。 特此公告。 ...

2020 年第三季度报告 公司代码：603567 公司简称：珍宝岛 黑龙江珍宝岛药业股份有限公司 2020 年第三季度报告 1 / 27 2020 年第三季度报告 一、 重要提示 二、 公司基本情况. 11[ 重要事项 四、 附录 目录 2 / 27 2020 年第三季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人方同华、主管会计工作负责人王磊及会计机构负责人（会计主管人员）王磊保证 季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | |------------------------------------------------|------------------------------|------------------------------------|- ...